A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

Inclusion Criteria: * Aged between 18 and 50 years * Able to understand the content of informed consent and signed the informed consent * Able and willing to complete all the secluded study process during the whole study follow-up period (about 6 months). * Negative in HIV diagnostic blood test on day of enrollment * Axillary temperature ≤37.0°C on the day of enrollment * Non-pregnant females with a negative result in the urine pregnancy test on day of enrollment * General good health as established by medical history and physical examination. Exclusion Criteria: * Infected by Ebola virus (inquiry) * Vaccination with other Ebola vaccine (inquiry) * HIV infection or other serious immunodeficiency disease (inquiry) * Allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV, such as mannitol * Family history of brain or mental disease * Woman who is pregnant or breast-feeding * Any acute fever disease or infections in last 7 days * Major congenital defects or not well-controlled chronic illness * Asplenia or functional asplenia * Platelet disorder or other bleeding disorder * Faint at the sight of blood or needles. * Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months * Prior administration of other research medicines in last 1 month * Prior administration of attenuated vaccine(s) in the last one month * Prior administration of inactivated vaccine(s) in the last 14 days * Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives